SYSTEMATIC REVIEW article
Front. Microbiol.
Sec. Infectious Agents and Disease
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1672925
Comparison of the efficacy and safety of baloxavir versus those of oseltamivir in pediatric patients with influenza: a meta-analysis
Provisionally accepted
Sheng Chen1*
Lingling Hua2- 1Department of Pediatrics, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China
- 2Department of Pediatrics, Women and Children’s Hospital of Ningbo University, Ningbo, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Baloxavir is a ribonucleic acid polymerase inhibitor that effectively alleviates influenza symptoms in adults and adolescents. This meta-analysis aimed to comprehensively compare the efficacy and safety of baloxavir with those of oseltamivir in pediatric patients with influenza. Methods: A comprehensive study search was performed by encompassing multiple electronic databases, including PubMed, Web of Science, Embase, the Cochrane Library, Wan Fang, VIP, and CNKI, from database establishment to June 2025. Studies comparing the efficacy and safety of baloxavir and oseltamivir in pediatric patients with influenza were included. Results: A total of 10 studies, including 2106 patients receiving baloxavir and 2567 patients receiving oseltamivir, were included in the analysis. The pooled analysis indicated that baloxavir resulted in a shorter duration of symptoms and duration of fever than did oseltamivir (both P<0.01). In the subgroup analysis, the statistical significance of the duration of symptoms remained unchanged in the subgroups of influenza types A and B, as well as in influenza A subtypes H1N1pdm09 and H3N2A (all P<0.05). However, in terms of the duration of fever, the advantage of baloxavir over oseltamivir was observed in the influenza type A (P<0.001) and B (P<0.001) subgroups and in the influenza A subtype H1N1pdm09 (P<0.001) subgroup but not in the H3N2A subgroup (P=0.430). The incidence of any AE was similar between the two groups (P=0.260). The quality of the enrolled studies was high, and there was no publication bias. Conclusion: In pediatric patients with influenza, baloxavir results in a shorter duration of symptoms and fever compared to oseltamivir, which may be attributed to their different bioavailability and half-lives. Additionally, the safety profiles of baloxavir and oseltamivir are comparable.
Keywords: baloxavir, Oseltamivir, influenza, efficacy and safety, Meta-analysis
Received: 25 Jul 2025; Accepted: 05 Sep 2025.
Copyright: © 2025 Chen and Hua. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sheng Chen, Department of Pediatrics, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.